Anti-Epidermal Antibody (Anti-EA) is a biomarker for diagnosing and managing autoimmune blistering skin disorders such as pemphigus vulgaris and bullous pemphigoid.
Anti-EA refers to autoantibodies that target proteins within the epidermis, the outermost layer of the skin. These antibodies primarily attack desmosome or hemidesmosome proteins, disrupting the adhesion between skin cells. This leads to blisters, skin erosion, and inflammation.
Clinically, Anti-EA is used to identify autoimmune skin disorders. Anti-skin antibodies are present in over 90% of active pemphigus cases, about 70% of bullous pemphigoid, 50% of vesicular pemphigoid and EBA, and 10% of cicatricial pemphigoid cases.
It’s especially helpful in distinguishing autoimmune skin conditions from other dermatological issues. Early detection of anti-EA can support effective management of a patient’s condition and prevent further complications.
Testing for Anti-EA is most relevant for patients presenting with chronic skin conditions. If a patient has persistent skin blistering, erosions, or lesions that do not respond to standard treatments, Anti-EA testing is indicated. It's particularly useful for suspected cases of pemphigus vulgaris or bullous pemphigoid.
In addition, individuals with systemic autoimmune diseases like lupus or rheumatoid arthritis may develop dermatological symptoms as part of their condition. Testing Anti-EA in these patients helps identify whether they have comorbid autoimmune skin conditions, which could influence treatment plans.
Clinicians may also consider testing patients with a family history of autoimmune skin conditions.
The following section outlines the test procedure and interpretation:
Anti-EA testing is typically performed using Immunofluorescence Assay (IFA), which detects the presence of Anti-EA antibodies in the patient’s serum. A blood draw is required, and no special preparation is necessary for the patient.
However, clinicians should note that immunosuppressive therapies can influence antibody levels, so they may need to consider this when interpreting test results.
Normal reference ranges for Anti-EA typically show either negative or very low levels of antibodies. As an example, one laboratory reports the following reference ranges for this test:
Intercellular Substance Ab Negative
Titer <1:10
Basement Membrane Zone Ab Negative
Titer <1:10
Reference ranges can vary slightly depending on the laboratory conducting the test, so clinicians should consult the specific laboratory's guidelines when interpreting the results.
Elevated levels of Anti-EA indicate active autoimmune processes, often associated with conditions like pemphigus vulgaris and bullous pemphigoid. High titers of Anti-EA correlate with increased disease severity, including chronic blistering, mucosal damage, scarring, and a heightened risk of secondary infections.
These patients are typically in an active phase of their disease, and their condition may progress. Intensive treatments, including corticosteroids, immunosuppressants, or biologics such as rituximab, may be considered.
Regular monitoring of Anti-EA levels can help clinicians to track disease progression, adjust treatments, and prevent complications.
Low or negative levels of Anti-EA typically indicate that the patient is in remission or does not have an active autoimmune blistering disorder like pemphigus vulgaris or bullous pemphigoid.
Negative results help rule out these conditions, but clinicians should remain cautious, as false negatives can occur, especially in the early stages of a disease or after immunosuppressive treatment.
Negative results may also suggest alternative diagnoses, such as eczema or dermatitis. Therefore, negative Anti-EA levels should be interpreted in the context of the patient’s overall clinical presentation.
Click here to compare testing options and order antibody test panels.
Ávalos-Díaz E, Herrera Esparza R. Dermatological autoimmune diseases. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside [Internet]. Bogota (Colombia): El Rosario University Press; 2013 Jul 18. Chapter 34. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459479/
Baigrie D, Nookala V. Bullous Pemphigoid. [Updated 2023 Mar 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535374/
Diaz, M. J., Natarelli, N., Wei, A., Rechdan, M., Botto, E., Tran, J. T., Forouzandeh, M., Plaza, J. A., & Kaffenberger, B. H. (2023). Cutaneous Manifestations of Rheumatoid Arthritis: Diagnosis and Treatment. Journal of personalized medicine, 13(10), 1479. https://doi.org/10.3390/jpm13101479
Ingold CJ, Sathe NC, Khan MAB. Pemphigus Vulgaris. [Updated 2024 Mar 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560860/
Lupus and your skin: Signs and symptoms. (n.d.). Www.aad.org. https://www.aad.org/public/diseases/a-z/lupus-symptoms
Oxford. (2023). Epidermal Antibodies - Immunology Laboratory. Ouh.nhs.uk. https://www.ouh.nhs.uk/immunology/diagnostic-tests/tests-catalogue/epidermal-antibodies.aspx
Quest Diagnostics: Test Directory. (2025). Questdiagnostics.com. https://testdirectory.questdiagnostics.com/test/test-detail/37097/epidermal-antibodies-with-reflex-to-titer?cc=MASTER
Tampoia, M., Bonamonte, D., Filoni, A., Garofalo, L., Morgese, M. G., Brunetti, L., Di Giorgio, C., & Annicchiarico, G. (2013). Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa. Orphanet journal of rare diseases, 8, 132. https://doi.org/10.1186/1750-1172-8-132